To conclude, patients with a GPS of 2 had significantly inferior survival compared to patients scoring 0 and 1. As a supplement to traditional patient‐related and newer disease‐related factors, using simple, inexpensive and accessible parameters such as the CRP and albumin at the time of diagnosis could aid decision‐making and prognostication in patients with newly diagnosed AML who are considered eligible for induction therapy. Further larger and prospective studies should further evaluate the prognostic impact of CRP and albumin levels in AML. This evidence concerns the gene ALB and acute myeloid leukemia.